The effect of heparin gel in improving hand and foot syndrome in patients treated with capecitabine
Phase 3
Recruiting
- Conditions
- cancer patient.Malignant neoplasm of connective and soft tissue of head, face and neckC49.0
- Registration Number
- IRCT20230215057423N1
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Newly diagnosed cancer patients for gastrointestinal tract and head and neck cancer treated with capecitabine and have evidence of early onset of hand-foot syndrome (grade 1 from onset)
Exclusion Criteria
The patient already has a skin or inflammatory disease
The patient's unwillingness to start the trial
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Examination of erythema, blisters and hyperkeratosis in hand and foot syndrome. Timepoint: Day zero and day twenty one. Method of measurement: Questionnaire and observation.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie heparin gel's efficacy in IRCT20230215057423N1 for capecitabine-induced hand and foot syndrome in cancer patients?
How does topical heparin gel compare to standard-of-care treatments like corticosteroids in managing capecitabine-induced hand and foot syndrome severity and recovery rates?
Which biomarkers correlate with improved hand and foot syndrome outcomes in cancer patients using topical heparin gel as an adjuvant to capecitabine therapy?
What are the safety profiles and adverse event management strategies for topical heparin gel in capecitabine-treated cancer patients with hand and foot syndrome?
What combination therapies or alternative compounds show efficacy in mitigating capecitabine-induced hand and foot syndrome compared to heparin gel?